AI News NQ Analysis

Commencement of Operations at the New Pharmaceutical Manufacturing Building at Alfresa Pharma Corporation's Gunma Plant

NQ Score 76/100
N1 Content Completeness 9

AI Summary (NQ-processed)

Alfresa Pharma has started operations at a new manufacturing building in its Gunma plant. It strengthens low-molecular drug production and fully enters contract manufacturing for highly active and sterile formulations.

AI Analysis

Frequently Asked Questions

Q: What does the new manufacturing building of Alfessa Pharma manufacture?
A: In addition to low molecular weight drugs, it manufactures high pharmacological activity formulations, and conducts inspections, packaging, and testing of sterile formulations.
Q: What is TSCS (Total Supply Chain Service)?
A: It is a service provided by the Alfessa Group that supports the entire process from drug development and manufacturing to logistics, sales, and post-market surveillance.
Q: What kind of service is PATH-Solution?
A: It is a platform that removes barriers for emerging biotech companies from overseas when entering the Japanese market and provides comprehensive support.